Ken Griffin Rhythm Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$35.41 - $44.37 $810,888 - $1.02 Million	-22,900 Reduced 34.49%	43,500 $1.79 Million
Q1 2024 May 15, 2024	SELL	$39.12 - $52.44 $293,400 - $393,300	-7,500 Reduced 10.15%	66,400 $2.88 Million
Q4 2023 Feb 14, 2024	BUY	$21.39 - $49.64 $1.19 Million - $2.76 Million	55,600 Added 303.83%	73,900 $3.4 Million
Q3 2023 Nov 14, 2023	BUY	$15.81 - $27.8 $41,106 - $72,280	2,600 Added 16.56%	18,300 $419,000
Q2 2023 Aug 14, 2023	SELL	$16.32 - $21.15 $267,648 - $346,860	-16,400 Reduced 51.09%	15,700 $258,000
Q1 2023 May 15, 2023	SELL	$16.88 - $34.24 $221,128 - $448,544	-13,100 Reduced 28.98%	32,100 $572,000
Q4 2022 Feb 14, 2023	SELL	$22.25 - $30.25 $3.6 Million - $4.89 Million	-161,600 Reduced 78.14%	45,200 $1.32 Million
Q3 2022 Nov 14, 2022	SELL	$4.3 - $30.85 $42,570 - $305,415	-9,900 Reduced 4.57%	206,800 $5.07 Million

178

69.1M

467K

224K

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $2.69B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.